Extended Data Fig. 5: The ether lipid biosynthesis pathway, but not other peroxisomal pathways, contributes to ferroptosis susceptibility.
From: Plasticity of ether lipids promotes ferroptosis susceptibility and evasion
a, Immunoblot analysis of AGPS levels in cells expressing the indicated constructs. Plot of experiment performed once. b, Viability curves of AGPS sg2-expressing OVCAR-8 cells rescued with sgRNA-resistant mouse Agps cDNA and being treated with indicated concentrations of RSL3 for 24 h. n = 4 biologically independent samples. Plot of experiment performed once. c, Viability curves of FAR1 sg2-expressing OVCAR-8 cells rescued with sgRNA-resistant mouse Far1 cDNA and being treated with indicated concentrations of RSL3 for 24 h. n = 4 biologically independent samples. Plot of experiment performed once. d, Viability curves for OVCAR-8 cells expressing empty vector or cDNAs of mouse Agps, Far1, Pex3 or Pex10 and treated with indicated concentrations of ML210 or RSL3. In this experiment, cellular viability was read at 24 h of treatment (instead of normally at 72 h), at which time point the control cells were not yet dying. n = 4 biologically independent samples. Plot of experiment performed once. e, Viability curves of 786-O cells expressing non-targeting negative control shRNA (shNC) or FAR1-targeting shRNAs treated with indicated concentrations of ML210 or RSL3 for 48 h. n = 4 biologically independent samples. Representative data of experiment performed twice. f, Viability curves of 786-O cells expressing shNC or GNPAT-targeting shRNAs treated with indicated concentrations of ML210 or RSL3 for 48 h. n = 4 biologically independent samples. Representative data of experiment performed twice. g, Percentage of remaining DPPH levels in in vitro DPPH assay system containing indicated concentrations of ZINC-69435460 or ferrostatin-1 (Fer-1). n = 3 biologically independent samples. Data are mean ± s.d. ZINC-69435460 vs Fer-1 both at 1 mM, P = 6.05x10e-8. h, Relative viability of OVCAR-8 cells pre-treated with AGPS inhibitor ZINC-69435460 (ZINC) for 24 h, followed by ML210 treatment for another 72 h. n = 3 biologically independent samples. Data are mean ± s.e.m. Representative data of experiment performed in triplicate. For 0.25 μM ML210 conditions, 0 μM vs 150 μM ZINC, P = 0.000076; vs 250 μM ZINC, P = 0.000073; vs 350 μM ZINC, P = 0.00011; vs 500 μM ZINC, P = 0.00045. For 0.35 μM ML210 conditions, 0 μM vs 150 μM ZINC, P = 0.0017; vs 250 μM ZINC, P = 0.000011; vs 350 μM ZINC, P = 7.55x10e-9; vs 500 μM ZINC, P = 0.00015. i, Immunoblot analysis of catalase (CAT) protein levels in 786-O cells expressing sgNC or CAT-targeting sgRNAs. Plot of experiment performed once. j, Immunoblot analysis of superoxide dismutase 1 (SOD1) levels in 786-O cells expressing sgNC or SOD1-targeting sgRNAs. Plot of experiment performed once. k, Viability curves of 786-O cells expressing sgNC or SOD1- or CAT-targeting sgRNAs treated with indicated concentrations of ML210 or RSL3 for 48 h. n = 4 biologically independent samples. Plots of experiment performed once. β-Actin was used as a loading control in immunoblots. See Supplementary Information for uncropped immunoblot images. For viability curves, data are mean ± s.d. P values were calculated using two-tailed Student’s t-tests.
